Geneoscopy

📍 St. Louis, United States🗓 Founded 2015👥 62 employees💰 Last funded Dec 2021
Biotechnology Research🌐 geneoscopy.com
Website LinkedIn
Geneoscopy is a life sciences company with the mission to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Geneoscopy’s lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded a Breakthrough Device Designation from the FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Our initial prospective clinical study demonstrates that the diagnostic can detect these lesions with greater sensitivity than all existing noninvasive screening tests, thereby, serve as a potential aid in early detection and prevention of cancer. Geneoscopy is also developing diagnostics for the diagnosis and management of inflammatory bowel disease in partnership with biopharmaceutical companies and leading academic research institutions.
2
Total investors
1
Early stage
0
Mid stage
1
Late stage
2015
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Geneoscopy?
Geneoscopy has 2 investors on record on gritt.io, including 1 early-stage backers and 1 late-stage investors.
When did Geneoscopy last raise funding?
The most recent investment in Geneoscopy recorded on gritt.io was in December 2021.
When was Geneoscopy founded?
Geneoscopy was founded in 2015.
What industry is Geneoscopy in?
Geneoscopy operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Geneoscopy based?
Geneoscopy is headquartered in St. Louis, United States.